Takeda Pharmaceutical is planning a $725 million overhaul of its research and development efforts.
United States Rep. Ted Lieu (D-Torrance) is urging Congress to tighten requirements governing medical device warnings, in light of the discovery that Olympus told U.S. executives not to issue a warning to hospitals regarding a possible deadly infection from tainted scopes.
Seres Therapeutics reported results from an interim phase 2 trial for its colon infection treatment. The results found the treatment was not statistically significant.
The FDA approved AbbVie’s new drug application for VIEKIRA XR extended-release tablets.
Galmed Pharmaceuticals named Ran Oren, MD, chief medical officer.
More articles on GI/endoscopy:
Dr. Kimberly Kolkhorst joins Essentia Health: 3 notes
Seres Therapeutics’ Phase 2 clinical trial results for C. Diff treatment not statistically significant; company stock plummets: 7 points
St. Mary’s Hospital settles lawsuit related to endoscopy death; investigation of gastroenterologist closed: 6 things to know
